Stocktoria

Bio Green Med Solution, Inc. BGMS

Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
2/9
Piotroski F — financial health
-178.61
Altman Z″ — distress risk · distress
Dividend payout · no dividend

Financials (annual, from 10-K)

FYRevenueNet incomeGross profitFree cash flowEquity
2025$0-$3.0M$6.8M
2024$43,000-$11.2M-$2.2M
2023$420,000-$22.6M-$16.1M$607,000
2022$0-$21.2M-$20.8M$15.9M
2021$0-$18.9M-$18.6M$37.7M
2020$0-$8.4M-$8.0M$33.3M

Recent insider activity (Form 4)

InsiderRoleDateActionSharesPrice
Kiu Cu SengChief Financial Officer2025-11-12Grant200,000$1.40
Doris Wong Sing EeChief Executive Officer2025-11-12Grant300,178$1.40
Yap Kim Choy10% owner2025-11-05Sell28,540$1.70
Yap Kim Choy10% owner2025-11-05J467,535
Kua Khai Loon10% owner2025-11-05J467,535
Ong Yee Lung10% owner2025-11-05J467,535
Yap Kim Choy10% owner2025-10-30Sell112,260$1.81
Kua Khai Loon10% owner2025-10-30Sell242,477$1.80

Why these scores methodology →

Piotroski F-score: 2/9

  • Positive return on assets
  • Positive operating cash flow
  • Rising ROA
  • Cash flow exceeds net income
  • Lower long-term debt
  • Rising current ratio
  • No share dilution
  • Rising gross margin
  • Rising asset turnover

Altman Z″: -178.61 (distress)

  • Working capital / assets 0.602
  • Retained earnings / assets -55.518
  • EBIT / assets -1.03
  • Equity / liabilities 5.095

Source: SEC EDGAR filings · CIK 0001130166 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.